ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49386
0.15%
Bitcoin
66,238.48
-1.05%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aileron Therapeutics Inc (ALRN)

  7. Aileron Therapeutics Inc (ALRN) News

ALRN

Aileron Therapeutics (ALRN)

Aileron Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALRN
DateTimeSourceHeadlineSymbolCompany
17/05/202407:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
17/05/202407:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
16/05/202407:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
16/05/202407:13GlobeNewswire Inc.Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ALRNAileron Therapeutics Inc
16/05/202407:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALRNAileron Therapeutics Inc
07/05/202406:05GlobeNewswire Inc.Aileron Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ALRNAileron Therapeutics Inc
04/05/202406:05GlobeNewswire Inc.Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202422:45GlobeNewswire Inc.Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionNASDAQ:ALRNAileron Therapeutics Inc
01/05/202422:30GlobeNewswire Inc.Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:ALRNAileron Therapeutics Inc
16/04/202407:20GlobeNewswire Inc.Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ALRNAileron Therapeutics Inc
12/03/202423:00GlobeNewswire Inc.Aileron Therapeutics Announces CEO TransitionNASDAQ:ALRNAileron Therapeutics Inc
07/03/202409:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
29/02/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
16/02/202408:05GlobeNewswire Inc.Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventNASDAQ:ALRNAileron Therapeutics Inc
13/02/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
06/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALRNAileron Therapeutics Inc
06/02/202405:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALRNAileron Therapeutics Inc
02/02/202408:30GlobeNewswire Inc.Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024NASDAQ:ALRNAileron Therapeutics Inc
01/02/202408:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALRNAileron Therapeutics Inc
30/01/202408:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALRNAileron Therapeutics Inc
30/01/202408:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALRNAileron Therapeutics Inc
30/01/202400:48Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALRNAileron Therapeutics Inc
30/01/202400:46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALRNAileron Therapeutics Inc
30/01/202400:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
25/01/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
20/01/202408:44Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALRNAileron Therapeutics Inc
12/01/202408:18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALRNAileron Therapeutics Inc
11/01/202408:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALRNAileron Therapeutics Inc
19/12/202309:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
22/11/202308:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALRNAileron Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALRN

Your Recent History

BIT
P20OH7
NLBNPIT20OH7 20240920 33...
BIT
F18585
Vontobel Financial Produ...
GATE
HCTUSDT
Hurricane Swap
COIN
PCPPUST
PET CASTLE PROTOCOL
EU
N854S
N854S
BFNX
BCHUSD
BIT
P1YYH6
NLBNPIT1YYH6 20991231 0....
TSXV
SXG
BIT
P1ZRT2
NLBNPIT1ZRT2 20351221 84...
COIN
QFILUST
BIT
F39649
Vontobel Financial Produ...
BIT
P1Y0A3
NLBNPIT1Y0A3 20240621 14.7
USOTC
RANJF
Randstad Holding Nv (PK)
BIT
P214Z9
NLBNPIT214Z9 20991231 43...
BIT
P224Z8
NLBNPIT224Z8 20240515 37...
COIN
ENXUST
ENEX.SPACE
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved